Clinical Trial Update: Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting results for nivolumab with or without ipilimumab in patients with persistent or recurrent ovarian, fallopian tube, or primary per…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-09-11